3 unchanged sentences
001-38079), filed with the SEC on May 18, 2017).
−Removed: Asset Purchase Agreement by and among the Registrant and IconOVir Bio, Inc., dated as of February 14, 2025, as amended March 18, 2025.
+Added: 2019 Inducement Plan, as amended.
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
The cover page from the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL
−Removed: Certain information in this exhibit has been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type of information that the registrant treats as private or confidential.
−Removed: Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
+Added: Management contract or compensatory plan.
The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference.
1 unchanged sentence
UroGen Pharma Ltd.
+Added: August 7, 2025
/s/ Elizabeth Barrett
2 unchanged sentences
(Principal Executive Officer)
+Added: August 7, 2025
/s/ Chris Degnan
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.